Northwire Canada EditionTuesday, August 25, 2026
Northwire
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Financings Routine +

Charlotte's Web Announces Closing of Transaction with British American Tobacco, Including US$10 Million Investment

Charlotte's Web Closes BAT Deal, Eliminating Debt Overhang but Facing Dilution and Revenue Headwinds

Executive Summary
  • Charlotte's Web Holdings, Inc. has officially closed its transaction with British American Tobacco (BAT) subsidiary BT DE Investments Inc.
  • The deal involved converting approximately C$89.6 million in outstanding convertible debentures and accrued interest into common shares at a conversion price of C$0.94 per share.
  • Concurrently, BAT invested US$10 million in new cash proceeds via a private placement equity investment at the same subscription price of C$0.94 per share.
  • Total shares issued to BAT amount to 109,944,042 common shares, representing approximately 40.6% ownership of the combined company post-closing.
  • Proceeds from the private placement will support participation in the anticipated CMMI Medicare pilot program and other medical channel initiatives.
  • The transaction is subject to final approval from the Toronto Stock Exchange (TSX), which appears to have been satisfied given the closing announcement.
Material Impact
  • Debt Elimination: The conversion removes approximately US$65 million in debt liability, significantly strengthening the balance sheet and eliminating ~US$3 million in annual interest costs plus ~US$12 million in future interest through 2029. This is a critical solvency improvement.
  • Dilution Risk: BAT now holds ~40% of outstanding shares. While this provides strategic backing, it represents massive dilution for existing shareholders and limits upside potential unless BAT drives significant value creation.
  • Market Expectations: The transaction was announced in March 2026 (NewsId 48016) and approved by shareholders on May 28, 2026 (NewsId 2496565). The closing news confirms execution of a known plan rather than introducing new information.
  • Stock Price Reaction: The stock has traded significantly lower from its February peak ($1.29) to the current level ($0.70), suggesting the market may have already priced in the dilution and debt conversion benefits months ago.
  • Operational Context: Q1 2026 revenue declined to $11.2 million (down from $12.3 million YoY). The financing does not immediately address top-line growth, which remains a concern despite balance sheet repair.
CWEB · Price
Company Overview
  • Company: Charlotte's Web Holdings, Inc. (CWEB/CWBHF).
  • Flagship Project: DeFloria Phase 2 clinical trial for AJA001 oral solution targeting irritability associated with autism spectrum disorder (ASD).
  • Core Business: CBD/Hemp-derived wellness products including oils, gummies, and topicals under the Charlotte's Web and Brightside brands.
  • Strategic Pivot: Transitioning from consumer CBD to medical channel reimbursement via Medicare/Medicaid pilot programs and pharmaceutical drug development.
Read the original news release →

More from CHARLOTTE'S WEB HOLDINGS, INC.